Advanced Biotech Valuation With Mechanism-Aware PoS and Long-Hop Reasoning
Defend probability of success and valuation assumptions by tracing target biology, comparator trials, biomarkers, patents, sponsor history, market context, and evidence strength.
Decision questions
What this solution is built to answer.
Why should this asset's PoS differ from phase and therapeutic-area base rates?
Which evidence chains support or weaken the valuation assumptions?
How do target biology, comparator readouts, biomarkers, patents and sponsor execution change the investment view?
What trace should a deal team or board see before accepting the valuation case?
Science and method
What can change the model or gate.
Long-hop traversal across disease, target, compound, trial, literature, patent, company and deal evidence.
Mechanism-aware probability of success that can incorporate target validation, comparator outcomes, biomarkers, readouts and sponsor execution.
Traceable assumption defense for rNPV, real options, Monte Carlo distributions and portfolio decisions.
Evidence-backed deliverables that connect the graph path to the valuation memo, model and board narrative.
Reasoning graphics
How ARiDA turns evidence chains into valuation defenses.
The cards below keep the original hop-chain visuals, but place them inside the standalone advanced valuation solution so the graphics support this specific use case.
- 01 / Target identification6-hop traversal
From a disease question to a druggable shortlist.
Disease genetics, mechanism support, druggability, patent evidence and assay readiness connected to the shortlist.
DiseaseTargetsCompoundsLiteraturePatentsTrialsOutputDeliverableTarget shortlist scored on genetic support, druggability, freedom-to-operate, and assay readiness.
vs. PubMed keyword searchA keyword query for "disease X drug target" returns papers without resolving druggability, patent evidence or the comparator landscape.
- 02 / Probability of success7-hop traversal
Mechanism-aware PoS, not historical base rates.
Beta-binomial priors anchored on the indication class, posterior updates on every readout. Updates as the science changes.
TargetsCompoundsComparator trialsLiteratureBiomarker evidenceDrug profileSponsor track recordOutputDeliverablePosterior PoS curve with an 80% credible band, event-stamped milestones and source-linked assumptions.
vs. Hay 2014 / Wong-Siah-Lo 2019Base-rate methods compute PoS from two variables: phase × therapeutic class. They cannot incorporate target-specific genetic support, biomarker stratification, comparator readouts, or sponsor execution history.
- 03 / Competitive positioning5-hop traversal
Where the asset stands against the comparator set.
Trial endpoints, safety profiles, label breadth, payer precedent and IP runway grounded in primary records.
DrugsComparator trialsCompaniesPatents / LOELiteratureOutputDeliverableTPP radar + positioning scatter + LOE waterfall, all triangulated against named comparators.
vs. side-by-side label comparisonReading FDA labels in parallel tells you what the comparators say. It does not tell you trial-level efficacy / safety, real-world usage, payer access, or LOE timing.
- 04 / White-space mapping6-hop traversal
Indications nobody has filed in.
Disease landscape, active programs, mechanism gaps and patent evidence connected to the indications still open for review.
DiseasesTargetsActive drugsPipelinePatent evidenceSponsor activityOutputDeliverableWhite-space map with indication addressability, IP runway, and competitive heat scored per cell.
vs. ClinicalTrials.gov keyword filterFiltering trial registries surfaces what is being run, not what is missing. Without the patent and target layers, true white space is invisible.
Method and decision gates
How the case is computed and reviewed.
| Workflow | Role | Artifacts |
|---|---|---|
| valuation-enterprise-workflow | Advanced valuation with assumption defense | PoS trace, rNPV assumptions, real-options context, board narrative |
| competitive-landscape-deepdive | Comparator evidence and competitive pressure | TPP radar, comparator evidence, LOE and positioning analysis |
| patent-landscape-analysis | Patent evidence and exclusivity context for counsel review | Patent families, assignees, jurisdictions, filing trends |
Evidence inputs
Supporting evidence, rights and decision inputs.
Decision record
What remains available for review.
Deliverables
Mechanism-aware PoS rationale with source trace.
Valuation assumption register tied to evidence paths.
Comparator and IP evidence pack for diligence.
Committee narrative explaining why the valuation case is or is not defensible.
Proof points
The page treats PoS as an evidence-updated judgment rather than a static base-rate lookup.
Long-hop reasoning makes visible which sources, links and inference order support the conclusion.
Advanced valuation connects science, competitive position, IP and finance in one decision trace.
Limits and review conditions
What this result does not establish.
Mechanistic evidence can inform a PoS adjustment, but expert review remains responsible for the accepted probability case.
FAQ
Common evaluation questions.
Is this different from standard rNPV?
Yes. rNPV is the financial wrapper. Advanced valuation focuses on defending the PoS and key assumptions with linked biological, clinical, competitive, IP and execution evidence.
Can this replace expert judgment?
No. It structures and traces the evidence so expert judgment is faster, more explicit and easier to defend in a committee setting.
Related solutions
Biotech Valuation
Connect scientific evidence and uncertainty to PoS, rNPV, option value and the asset or portfolio decision under review.
Real Options Analysis
Quantify the value of strategic flexibility in biotech R&D with binomial lattices, Longstaff-Schwartz Monte Carlo, compound options, Greeks, exercise boundaries, and option-value decomposition.
Competitive Intelligence
Build competitive landscapes, TPP comparisons, patent-cliff views, market-share scenarios, and response plans from live web, trial, patent, literature, and database evidence.
Related reading
Build a biotech valuation case that exposes its science
A credible valuation connects scientific support, uncertainty and commercial assumptions to the value distribution.
Why committee outputs need a computation record
The memo should summarize an inspectable case, not substitute for one.
Design scientific decision systems around methods, not prompts
Stable calculators, evidence contracts and explicit gates should carry repeatable parts of the work.